Analysts think ALKS stock price could increase by 27%
May 06, 2025, 11:26 AM
0.43%
What does ALKS do
Alkermes Plc is a biopharmaceutical company based in Dublin, focused on developing treatments for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, employing 2,100 people. Its key products include LYBALVI, ARISTADA, and VIVITROL, with ongoing development for neurological disorders and cancer.
16 analysts think ALKS stock price will increase by 26.69%. The current median analyst target is $39.78 compared to a current stock price of $31.40. The lowest analysts target is $30.30 and the highest analyst target is $54.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
